Assenagon Asset Management’s AbbVie ABBV Stock Holding History

Assenagon Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$528M	Buy	2,097,882 +748,838	+56%	+$161M	0.66%	22
2026 Q1	$293M	Sell	1,349,044 -1,608,836	-54%	-$357M	0.45%	39
2025 Q4	$676M	Sell	2,957,880 -267,547	-8%	-$60.9M	0.93%	18
2025 Q3	$747M	Sell	3,225,427 -1,106,627	-26%	-$225M	1.02%	13
2025 Q2	$804M	Buy	4,332,054 +3,666,521	+551%	+$681M	1.19%	16
2025 Q1	$139M	Sell	665,533 -1,323,453	-67%	-$257M	0.23%	80
2024 Q4	$353M	Sell	1,988,986 -107,872	-5%	-$19.8M	0.57%	26
2024 Q3	$414M	Buy	2,096,858 +781,858	+59%	+$146M	0.76%	24
2024 Q2	$226M	Buy	1,315,000 +997,441	+314%	+$165M	0.5%	36
2024 Q1	$57.8M	Sell	317,559 -1,826,351	-85%	-$315M	0.14%	117
2023 Q4	$332M	Buy	2,143,910 +1,433,236	+202%	+$209M	0.88%	15
2023 Q3	$106M	Buy	710,674 +233,403	+49%	+$34.3M	0.33%	47
2023 Q2	$64.3M	Buy	477,271 +188,558	+65%	+$27.7M	0.22%	88
2023 Q1	$46M	Buy	288,713 +38,335	+15%	+$5.86M	0.16%	116
2022 Q4	$40.5M	Sell	250,378 -97,899	-28%	-$15M	0.15%	140
2022 Q3	$46.7M	Sell	348,277 -287,434	-45%	-$41.2M	0.18%	121
2022 Q2	$97.4M	Sell	635,711 -716	-0.1%	-$109K	0.36%	54
2022 Q1	$103M	Sell	636,427 -176,849	-22%	-$25.7M	0.29%	73
2021 Q4	$110M	Sell	813,276 -2,631,894	-76%	-$311M	0.32%	54
2021 Q3	$372M	Buy	3,445,170 +2,431,209	+240%	+$278M	1.19%	19
2021 Q2	$114M	Buy	1,013,961 +622,096	+159%	+$70.1M	0.39%	48
2021 Q1	$42.4M	Sell	391,865 -872,915	-69%	-$93.4M	0.17%	107
2020 Q4	$136M	Buy	1,264,780 +578,199	+84%	+$55.6M	0.59%	35
2020 Q3	$60.1M	Buy	686,581 +238,188	+53%	+$22.4M	0.34%	51
2020 Q2	$44M	Buy	448,393 +257,524	+135%	+$22.7M	0.28%	62
2020 Q1	$14.5M	Buy	+190,869	New	+$16.3M	0.12%	131
2019 Q3	–	Sell	-794,413	Closed	-$57.8M	–	811
2019 Q2	$57.8M	Buy	+794,413	New	+$62.4M	0.43%	48
2019 Q1	–	Sell	-28,792	Closed	-$2.65M	–	918
2018 Q4	$2.65M	Sell	28,792 -717,864	-96%	-$63.1M	0.03%	369
2018 Q3	$70.6M	Buy	746,656 +726,012	+3,517%	+$68.8M	0.7%	33
2018 Q2	$1.91M	Sell	20,644 -170,144	-89%	-$16.6M	0.02%	332
2018 Q1	$18.1M	Buy	190,788 +184,895	+3,138%	+$20.3M	0.24%	112
2017 Q4	$570K	Sell	5,893 -656,121	-99%	-$61.8M	0.01%	592
2017 Q3	$58.8M	Buy	662,014 +648,756	+4,893%	+$49.4M	0.55%	51
2017 Q2	$961K	Buy	+13,258	New	+$891K	0.02%	150

Other funds holding ABBV

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

HPC

HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

CRM

Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Assenagon Asset Management's ABBV Position: Q2 2026 in Review

Assenagon Asset Management increased its AbbVie (ABBV) stake by 56% in Q2 2026, buying an estimated $161M and bringing the position to 2,097,882 shares worth $528M. The position accounts for 0.66% of the portfolio, ranked #22.

Assenagon Asset Management first reported a position in ABBV in Q2 2017 and has held it in 34 quarters since. The position peaked at $804M in Q2 2025. 1,043 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Assenagon Asset Management held 2,097,882 shares of AbbVie worth $528M as of Q2 2026.
Assenagon Asset Management bought 748,838 AbbVie shares in Q2 2026, an estimated $161M.
AbbVie made up 0.66% of Assenagon Asset Management's portfolio in Q2 2026, its #22 holding.
Assenagon Asset Management first reported a position in AbbVie in Q2 2017 and has held it in 34 quarters since.
Assenagon Asset Management's AbbVie position peaked at $804M in Q2 2025.
1,043 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.